Dictionary.com
Thesaurus.com

sclerosis

American  
[skli-roh-sis] / sklɪˈroʊ sɪs /

noun

PLURAL

scleroses
  1. Pathology.  a hardening or induration of a tissue or part, or an increase of connective tissue or the like at the expense of more active tissue.

  2. Botany.  a hardening of a tissue or cell wall by thickening or lignification.


sclerosis British  
/ sklɪəˈrəʊsɪs /

noun

  1. pathol a hardening or thickening of organs, tissues, or vessels from chronic inflammation, abnormal growth of fibrous tissue, or degeneration of the myelin sheath of nerve fibres, or (esp on the inner walls of arteries) deposition of fatty plaques Compare arteriosclerosis atherosclerosis multiple sclerosis

  2. the hardening of a plant cell wall or tissue by the deposition of lignin

  3. a debilitating lack of progress or innovation within an institution or organization

"Collins English Dictionary — Complete & Unabridged" 2012 Digital Edition © William Collins Sons & Co. Ltd. 1979, 1986 © HarperCollins Publishers 1998, 2000, 2003, 2005, 2006, 2007, 2009, 2012

Other Word Forms

  • sclerosal adjective

Etymology

Origin of sclerosis

1350–1400; Middle English < Medieval Latin < Greek sklḗrōsis hardening. See scler-, -osis

Example Sentences

Examples are provided to illustrate real-world usage of words in context. Any opinions expressed do not reflect the views of Dictionary.com.

Since New Jersey resident Natalie Jeremias, 50, was diagnosed with multiple sclerosis earlier this year, she has struggled with getting treatments because of insurance denials and high deductibles.

From The Wall Street Journal

She currently receives disability benefits due to a multiple sclerosis diagnosis.

From Salon

Given adverse events seen with other trials, expectations for fenebrutinib in relapsing multiple sclerosis were modest, he says.

From The Wall Street Journal

And 1994 winners M People donated their prize to a multiple sclerosis charity after a friend was diagnosed with the condition.

From BBC

The Swiss pharmaceutical group said Monday that fenebrutinib met its primary endpoint in a Phase 3 clinical trial in patients with relapsing multiple sclerosis, the most common form of the disease.

From The Wall Street Journal